These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 19282424)

  • 1. Risperidone long-acting injection: factors associated with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up.
    Taylor D; Cornelius V
    J Psychopharmacol; 2010 Jul; 24(7):995-9. PubMed ID: 19282424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use.
    Taylor D; Fischetti C; Sparshatt A; Thomas A; Bishara D; Cornelius V
    Acta Psychiatr Scand; 2009 Aug; 120(2):97-101. PubMed ID: 19207128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health resource utilization associated with switching to risperidone long-acting injection.
    Young CL; Taylor DM
    Acta Psychiatr Scand; 2006 Jul; 114(1):14-20. PubMed ID: 16774656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Explicit review of risperidone long-acting injection prescribing practice.
    Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
    J Clin Pharm Ther; 2011 Dec; 36(6):651-63. PubMed ID: 22023342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients.
    Girardi P; Serafini G; Pompili M; Innamorati M; Tatarelli R; Baldessarini RJ
    Pharmacopsychiatry; 2010 Mar; 43(2):66-72. PubMed ID: 20099224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series.
    Se Hyun Kim ; Dong Chung Jung ; Yong Min Ahn ; Yong Sik Kim
    J Psychopharmacol; 2010 Jul; 24(7):981-6. PubMed ID: 19942641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice.
    Taylor DM; Fischetti C; Sparshatt A; Thomas A; Bishara D; Cornelius V
    J Clin Psychiatry; 2009 Feb; 70(2):196-200. PubMed ID: 19026261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome.
    Taylor DM; Young C; Patel MX
    Int J Neuropsychopharmacol; 2006 Dec; 9(6):685-94. PubMed ID: 16939663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry.
    Olivares JM; Peuskens J; Pecenak J; Resseler S; Jacobs A; Akhras KS;
    Curr Med Res Opin; 2009 Sep; 25(9):2197-206. PubMed ID: 19604073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study.
    Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):61-8. PubMed ID: 22776632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
    Peuskens J; Olivares JM; Pecenak J; Tuma I; Bij de Weg H; Eriksson L; Resseler S; Akhras K; Jacobs A
    Curr Med Res Opin; 2010 Mar; 26(3):501-9. PubMed ID: 20014981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
    Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions.
    Chengappa KN; Sheth S; Brar JS; Parepally H; Marcus S; Gopalani A; Palmer A; Baker RW; Schooler NR
    J Clin Psychiatry; 1999 Jun; 60(6):373-8. PubMed ID: 10401915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care.
    Taylor M; Currie A; Lloyd K; Price M; Peperell K
    J Psychopharmacol; 2008 Mar; 22(2):128-31. PubMed ID: 18308820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.
    Parellada E; Kouniakis F; Siurkute A; Schreiner A; Don L
    Int Clin Psychopharmacol; 2010 May; 25(3):149-54. PubMed ID: 20305567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable.
    Duncan EJ; Woolson SL; Hamer RM
    Int Clin Psychopharmacol; 2012 Sep; 27(5):283-90. PubMed ID: 22644368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia?
    Schmauss M; Diekamp B; Gerwe M; Schreiner A; Ibach B
    Pharmacopsychiatry; 2010 Mar; 43(2):73-80. PubMed ID: 20131207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.